{"schema_version":"1","generated_at":"2026-11-22T03:46:27.860Z","data_as_of":null,"url":"https://www.findmykol.com/kol/deepti-satelli","json_url":"https://www.findmykol.com/kol/deepti-satelli/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"deepti-satelli","name":"Deepti Satelli","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Kansas City","state":"MO","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Deepti Satelli is an Oncology physician. OpenAlex indexes 17 publications with 379 citations (h-index 6).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":17,"cited_by_count":379,"h_index":6,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":6,"program_years":{"first":2021,"last":null},"rows_total":7,"shown":3,"withheld":4,"rows":[{"payer":"Stemline Therapeutics Inc.","program_year":2025,"amount_usd":85.1,"payment_count":2},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":27.6,"payment_count":1},{"payer":"GlaxoSmithKline, LLC.","program_year":2024,"amount_usd":44.07,"payment_count":2}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":65,"classes_total":6,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":44.7,"drugs":[{"name":"Anastrozole","share_pct":60.2},{"name":"Letrozole","share_pct":23.5},{"name":"Exemestane","share_pct":16.3}],"max_beneficiaries":98},{"class":"Estrogen Agonist/Antagonist","setting":"prescribed","share_pct":11.8,"drugs":[{"name":"Tamoxifen Citrate","share_pct":100}],"max_beneficiaries":47}]},{"area":"Nervous system","share_pct":18,"classes_total":5,"classes":[{"class":"Gabapentinoids","setting":"prescribed","share_pct":8.9,"drugs":[{"name":"Gabapentin","share_pct":87},{"name":"Pregabalin","share_pct":13}],"max_beneficiaries":null},{"class":"Opioid Agonist","setting":"prescribed","share_pct":4.8,"drugs":[{"name":"Oxycodone Hcl","share_pct":45.2},{"name":"Tramadol Hcl","share_pct":30.6},{"name":"Morphine Sulfate Er","share_pct":24.2}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":6,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":6,"drugs":[{"name":"Eliquis","share_pct":81.8},{"name":"Xarelto","share_pct":18.2}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":85.6,"facility_pct":14.4},"source":"medicare"},"publications":{"total":17,"shown":5,"withheld":12,"matched_by":"OpenAlex author record","recent":[{"title":"Predictors of pathologic complete response following neoadjuvant TCHP in HER2-positive breast cancer.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12519","status":"verified"},{"title":"A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.2_suppl.730","status":"verified"},{"title":"Abstract PD7-11: Impact of neoadjuvant pembrolizumab on ovarian function in young patients with triple-negative breast cancer (TNBC): Longitudinal analysis from NeoSTOP and NeoPACT trials","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-pd7-11","status":"verified"},{"title":"Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer","year":2025,"journal":"International Journal of Radiation Oncology*Biology*Physics","source_url":"https://doi.org/10.1016/j.ijrobp.2025.09.038","status":"verified"},{"title":"Abstract P3-11-17: A Randomized Phase II Trial of Neo-adjuvant Chemotherapy with Metformin or Placebo for HER-2 Positive Operable Breast Cancer (The HERMET Trial)","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs24-p3-11-17","status":"verified"}],"source":"works"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":4,"publications":12}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}